Filing Flows › Moderna (MRNA) › RSV revenue
Moderna (MRNA) RSV revenue by quarter
Moderna's RSV revenue was $29.0M in Q3 2026 (third quarter 2026), +867% from Q2 2026. Over the last 6 quarters it ranged from $2.0M (Q3 2025) to $29.0M (Q3 2026).
| Quarter | RSV revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $29.0M | +867% | 14× |
| Q2 2026 | $3.0M | -57% | — |
| Q1 2026 | $7.0M | +75% | +250% |
| Q4 2025 | $4.0M | +100% | — |
| Q3 2025 | $2.0M | 0% | — |
| Q1 2025 | $2.0M | — | — |
Q3 2026 at a glance
Moderna, Q3 2026: revenue $1.3B (+29% year over year), operating margin 9.9%, net earnings $162M, operating cash flow −$1.6B. The chart follows the revenue to costs, profit and cash.
Questions
What is Moderna's RSV revenue?
Moderna's RSV revenue was $29.0M in Q3 2026 (third quarter 2026), +867% from Q2 2026.
How has Moderna's RSV revenue changed?
Over the last 6 quarters it ranged from $2.0M (Q3 2025) to $29.0M (Q3 2026).